Neuro3d SA
This article was originally published in Start Up
Executive Summary
Neuro3d SA proposes to take over early clinical development work for pharmaceutical partners. It will use its in-house expertise to bring promising compounds to Phase II, then offer its partners the chance to license compounds back, or to give rights to Neuro3d. The French start-up is specializing in compounds for CNS disorders, specifically schizophrenia, depression and anxiety.